Should You Buy Emergent Biosolutions Inc (EBS) Stock Tuesday Morning?

Emergent Biosolutions Inc (EBS) has fallen Tuesday morning, with the stock declining -5.92% in pre-market trading to 34.5. EBS's short-term technical score of 83 indicates that the stock has traded more bullishly over the last month than 83% of stocks on the market. In the Drug Manufacturers - Specialty & Generic industry, which ranks 141 out of 146 industries, Emergent Biosolutions Inc ranks higher than 94% of stocks. Emergent Biosolutions Inc has fallen 1.58% over the past month, closing at $37.02 on April 26. During this period of time, the stock fell as low as $27.97 and as high as $38.37. EBS has an average analyst recommendation of Buy. The company has an average price target of $48.17.

EBS has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on EBS!

See Full EBS Report

Emergent Biosolutions Inc has a Long-Term Technical rank of 42. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 58% of the market scoring higher. In the Drug Manufacturers - Specialty & Generic industry which is number 117 by this metric, EBS ranks better than 49% of stocks.

Important Dates for Investors in EBS:

-Emergent Biosolutions Inc is set to release earnings on 7/27/2022. Over the last 12 months, the company has reported EPS of $2.91. -We do not have a set dividend date for Emergent Biosolutions Inc at this time. Click Here To Get The Full Report on Emergent Biosolutions Inc (EBS)